V K Yang1, J E Rush2, S Bhasin3, A J Wagers4, R T Lee5. 1. Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, 200 Westboro Rd, North Grafton, MA, 01536, USA. Electronic address: vicky.yang@tufts.edu. 2. Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, 200 Westboro Rd, North Grafton, MA, 01536, USA. 3. Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA, 02115, USA. 4. Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Harvard University, 7 Divinity Ave, Cambridge, MA, 02138, USA; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, One Joslin Place, Boston, MA, 02215, USA; Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, 77 Ave. Louis Pasteur, Boston, MA, 02115, USA. 5. Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Harvard University, 7 Divinity Ave, Cambridge, MA, 02138, USA.
Abstract
OBJECTIVES: Growth differentiation factor (GDF) 11 has been shown to reduce cardiac hypertrophy in mice. Low levels of GDF-11 are associated with cardiac hypertrophy in humans. The authors hypothesized that plasma GDF-11 level is decreased in cats with hypertrophic cardiomyopathy (HCM). Given the close homology between GDF-11 and myostatin/GDF-8, GDF-8 levels were also assessed. ANIMALS: Thirty-seven client-owned cats were enrolled, including cats with normal cardiac structure (n = 16), cats with HCM or hypertrophic obstructive cardiomyopathy (HOCM; n = 14), and cats with HCM and congestive heart failure (CHF; n = 7). METHODS: Plasma samples were analyzed for GDF-8 and GDF-11 using liquid chromatography tandem-mass spectrometry. Levels of GDF-8 and GDF-11 were compared between cats with normal cardiac structure, HCM or HOCM, and CHF. RESULTS: No differences in GDF-11 concentrations were found between cats with normal cardiac structure and cats with HCM/HOCM, with or without history of CHF. Decreased GDF-8 concentrations were detected in cats with CHF compared to cats with HCM/HOCM without history of CHF (p=0.031) and cats with normal cardiac structure (p=0.027). Growth differentiation factor 8 was higher in cats with HOCM compared to those with CHF (p=0.002). No statistical difference was noted in GDF-8 level as a function of age, weight, or body condition score. CONCLUSIONS: Plasma GDF-11 was not different between cats with HCM/HOCM and cats with normal cardiac structure regardless of age. Plasma GDF-8 was decreased in cats with CHF compared to cats with normal cardiac structure and cats with asymptomatic HCM/HOCM, suggesting a possible role in CHF development.
OBJECTIVES:Growth differentiation factor (GDF) 11 has been shown to reduce cardiac hypertrophy in mice. Low levels of GDF-11 are associated with cardiac hypertrophy in humans. The authors hypothesized that plasma GDF-11 level is decreased in cats with hypertrophic cardiomyopathy (HCM). Given the close homology between GDF-11 and myostatin/GDF-8, GDF-8 levels were also assessed. ANIMALS: Thirty-seven client-owned cats were enrolled, including cats with normal cardiac structure (n = 16), cats with HCM or hypertrophic obstructive cardiomyopathy (HOCM; n = 14), and cats with HCM and congestive heart failure (CHF; n = 7). METHODS: Plasma samples were analyzed for GDF-8 and GDF-11 using liquid chromatography tandem-mass spectrometry. Levels of GDF-8 and GDF-11 were compared between cats with normal cardiac structure, HCM or HOCM, and CHF. RESULTS: No differences in GDF-11 concentrations were found between cats with normal cardiac structure and cats with HCM/HOCM, with or without history of CHF. Decreased GDF-8 concentrations were detected in cats with CHF compared to cats with HCM/HOCM without history of CHF (p=0.031) and cats with normal cardiac structure (p=0.027). Growth differentiation factor 8 was higher in cats with HOCM compared to those with CHF (p=0.002). No statistical difference was noted in GDF-8 level as a function of age, weight, or body condition score. CONCLUSIONS: Plasma GDF-11 was not different between cats with HCM/HOCM and cats with normal cardiac structure regardless of age. Plasma GDF-8 was decreased in cats with CHF compared to cats with normal cardiac structure and cats with asymptomatic HCM/HOCM, suggesting a possible role in CHF development.
Authors: Kristoff A Olson; Alexis L Beatty; Bettina Heidecker; Mathilda C Regan; Edward N Brody; Trudi Foreman; Shintaro Kato; Robert E Mehler; Britta S Singer; Kristian Hveem; Havard Dalen; David G Sterling; Richard M Lawn; Nelson B Schiller; Stephen A Williams; Mary A Whooley; Peter Ganz Journal: Eur Heart J Date: 2015-08-20 Impact factor: 29.983
Authors: Guo-Qing Du; Zheng-Bo Shao; Jie Wu; Wen-Juan Yin; Shu-Hong Li; Jun Wu; Richard D Weisel; Jia-Wei Tian; Ren-Ke Li Journal: Basic Res Cardiol Date: 2016-12-21 Impact factor: 17.165
Authors: Yue Zhao; Guowen Liu; Frank C Zambito; Yan J Zhang; Binodh S DeSilva; Alexander T Kozhich; Jim X Shen Journal: Anal Chim Acta Date: 2017-04-26 Impact factor: 6.558
Authors: Marissa J Schafer; Elizabeth J Atkinson; Patrick M Vanderboom; Brian Kotajarvi; Thomas A White; Matthew M Moore; Charles J Bruce; Kevin L Greason; Rakesh M Suri; Sundeep Khosla; Jordan D Miller; H Robert Bergen; Nathan K LeBrasseur Journal: Cell Metab Date: 2016-06-14 Impact factor: 27.287
Authors: Teresa A Zimmers; Yanling Jiang; Meijing Wang; Tiffany W Liang; Joseph E Rupert; Ernie D Au; Francesco E Marino; Marion E Couch; Leonidas G Koniaris Journal: Basic Res Cardiol Date: 2017-06-24 Impact factor: 17.165
Authors: Ryan G Walker; Tommaso Poggioli; Lida Katsimpardi; Sean M Buchanan; Juhyun Oh; Sam Wattrus; Bettina Heidecker; Yick W Fong; Lee L Rubin; Peter Ganz; Thomas B Thompson; Amy J Wagers; Richard T Lee Journal: Circ Res Date: 2016-04-01 Impact factor: 17.367